Congress traded patent term restoration for generic drug approval pathway

By the early 1980s, brand-name pharmaceutical companies and the generic drug industry were locked in a standoff neither side could break through Congress alone. Brand companies watched years of their patents' useful life quietly disappear while the FDA's own approval process dragged on, since a patent's fixed term started running the moment it was granted, regardless of how long regulatory review took to actually let the drug reach market.

Generic manufacturers, meanwhile, had just been dealt a serious blow: in 1984 the Federal Circuit ruled in Roche v. Bolar that even testing a patented drug to prepare a generic version — years before the patent expired, purely to gather the data the FDA would eventually require — counted as patent infringement. That ruling meant generics couldn't legally begin the FDA approval process until a patent had already expired, adding years of additional de facto exclusivity on top of whatever patent term remained.

Traded patent term restoration for a generic approval pathway, bundling both into one bill so each got what only the other's cooperation could deliver.

Each side had a concrete loss: brands lost patent years to FDA delays, generics lost legal prep time after Roche v. Bolar.

The two asks were severable and roughly balanced, so each side valued the other's concession enough to accept the trade.

Bundling forced a single vote, so neither lobby could oppose the bill without losing its own gain.

When two sides each block the other's fix, bundle their separate asks into one deal so both gain more from passing than blocking.

Both halves of the deal passed together on September 24, 1984, because each industry's lobby stood to gain more from the trade than from continuing to block the other side's ask indefinitely. Brand companies got their lost patent years restored; generic companies got a legal, far faster path to market the moment a patent expired — reshaping the economics of both industries for decades.